Lyon: Translational & Clinical Research Excellence
Complementing the Lyon region’s strong industrial footprint is a dense network of hospital facilities, only bettered by Paris on the national level. Across 13 hospitals in the Hospices Civils de…
The Swiss company SIGVARIS, 100% family-owned since it was founded, is the global market leader in the manufacture of medical compression garments and celebrated its 150th anniversary in 2014. The company was established in 1864 in Winterthur. For about 100 years, SIGVARIS produced “rubber-elastic textiles”, which it sold both in Switzerland and abroad.
From 1958 to 1960, the company collaborated with Dr. Karl Sigg and developed a medical compression stocking to improve venous function and relieve venous-related conditions. The product portfolio was expanded in 2009 when the WELL BEING and SPORTS lines were added to the main MEDICAL line. WELL BEING stockings have a preventive function and relieve the early symptoms of leg conditions. SPORTS products improve athlete performance and recovery time.
The company can look back at a successful track record as it moves continuously towards the future, in keeping with its motto “Every day a step further”. Customers around the world include pharmacies, chemists, orthopaedic and medical specialist stores as well as doctors and hospitals. The Group produced about 8 million pairs of stockings in 2014 and generated revenue of around CHF 250 million.
SIGVARIS Group
The Swiss Group SIGVARIS has its headquarters in Switzerland and is the global market leader in the manufacture of medical compression garments. It employs about 1,400 people and has its own production plants in Switzerland, France, the US and Brazil. SIGVARIS is close to its customers, having subsidiaries in Germany, Austria, England, Italy, Canada, China, Australia and the United Arab Emirates as well as distributors in more than 70 countries on all continents. The Group pursues an international growth strategy on the solid foundation of 150 years of success.
Contact
Rue Barthélémy Thimonnier, 42170 Saint-Just-Saint-Rambert, France
+33 4 77 36 08 90
Complementing the Lyon region’s strong industrial footprint is a dense network of hospital facilities, only bettered by Paris on the national level. Across 13 hospitals in the Hospices Civils de…
The Auvergne-Rhône-Alpes region, with Lyon at its heart, is France’s industrial heartland. Hosting over 500,000 manufacturing and manufacturing-related jobs, AURA is also the nation’s top destination the production of biologics,…
European biotech’s recent struggles are well documented. Deep-pocketed investors with sufficient risk tolerance to fund potentially breakout companies are thin on the ground, and Europe is losing touch with both…
Lyon’s leading biotechs have caught the eye of global pharma in recent years, with two major acquisitions attesting to the quality and sophistication of the ecosystem and laying a path…
Lyon – recently announced as the host of BIO-Europe Spring 2027 – has long played a vital role in global health and, in 2026, it stands as one of Europe’s…
Ophthalmology is a booming niche, with investment flowing in, M&A up, and a burgeoning cast of biotechs – including the three European leaders profiled below – vying for a share…
France and Denmark have a rich history of healthcare collaboration, from basic research to clinical trials, as well as major manufacturing investments. What links these two nations, and what are…
France is considered among the leading rare disease markets worldwide, both scientifically and organisationally. The country has cultivated a fully-fledged supporting ecosystem for rare conditions that is today regarded as…
France’s historical contribution to medical research is almost unparalleled globally, with 13 winners of the annual Nobel Prize for Physiology or Medicine, and even more for Chemistry. Most famously, Louis…
France’s patient advocacy network is one of Europe’s most well-developed and formalised. Patient advocacy groups – including the three featured below – fill in research, care, and support gaps left…
France may have ceded Europe’s top spot for the sheer number of clinical trial starts to Spain in 2023, but it remains one of Europe’s most strategically valuable destinations for…
Valued fifth globally in terms of overall revenues and enjoying year-on-year growth rates exceeding five percent, the French pharma market is undeniably one of the great global life science powerhouses,…
See our Cookie Privacy Policy Here
